NEW YORK (GenomeWeb News) – Vermillion said after the close of the market on Monday that it has sent Quest Diagnostics a notice of termination of their licensing deal covering the OVA1 and Vasclir diagnostic tests.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Two Johns Hopkins researchers discuss the need for evidence-based data analysis.

In PLOS this week: genes under positive selection in Plasmodium falciparum populations, genetic variation in Epstein-Barr viruses, and more.

Cancer clinical trial patients settle with Anil Potti and Duke University.

A trio of researchers is trying to raise money to sequence and analyze the genome of a cat with a suite of unusual traits.